| Size | Price | |
|---|---|---|
| 100g | ||
| Other Sizes |
| Targets |
EDTA dihydrate tripotassium targets metal ions (such as Ca²⁺, Mg²⁺, Fe³⁺, and other divalent and trivalent cations) through its chelating properties. The compound does not target a specific protein or enzyme but rather serves as a metal ion chelator that binds to metal ions, forming stable complexes and preventing them from participating in biological or chemical reactions. This chelating activity makes EDTA valuable as an anticoagulant in blood collection tubes and as a reagent for metal ion sequestration in various biochemical applications.
|
|---|---|
| ln Vitro |
The in vitro activity of EDTA dihydrate tripotassium is its function as a chelating agent. The compound binds metal ions such as Ca²⁺, Mg²⁺, and Fe³⁺, forming stable complexes. This chelating activity prevents metal ions from participating in enzymatic reactions or other biological processes that require divalent cations. EDTA is used as an anticoagulant in blood collection tubes for tissue and plasma samples. It is also used as a biochemical reagent for life science related research.
|
| ln Vivo |
EDTA dihydrate tripotassium is not used as a therapeutic agent. Its in vivo utility is limited to its use as an anticoagulant in blood collection and as a research reagent. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro assays for EDTA dihydrate tripotassium involve its use as a chelating agent to sequester metal ions. The compound is added to solutions containing metal ions, and the formation of EDTA-metal complexes can be monitored by various analytical techniques. In blood collection, EDTA is used to coat tubes to prevent coagulation by chelating calcium ions required for the coagulation cascade.
|
| Cell Assay |
For in vitro cellular experiments, EDTA dihydrate tripotassium is not typically used directly in cell-based assays due to its metal-chelating properties, which can disrupt cellular processes that depend on divalent cations. However, it may be used in cell culture media to chelate trace metals or in cell dissociation protocols.
|
| Animal Protocol |
In vivo animal experiments with EDTA dihydrate tripotassium are not commonly performed as a therapeutic intervention. The compound may be used in pharmacokinetic studies or as an anticoagulant for blood collection from animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of EDTA dihydrate tripotassium have been characterized in the context of its use as an anticoagulant. The compound is not absorbed systemically when used in blood collection tubes. It has a molecular weight of 442.54 g/mol and should be stored as powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
EDTA dihydrate tripotassium is intended for research and diagnostic use only and not for human therapeutic applications. Standard laboratory safety precautions should be observed when handling this chemical reagent.
|
| Additional Infomation |
EDTA dihydrate tripotassium (CAS#: 65501-24-8) is a chelating agent that binds metal ions, used as an anticoagulant in blood collection tubes and as a biochemical reagent for life science research. It has no clinical or therapeutic applications.
|
| Molecular Formula |
C10H17K3N2O10
|
|---|---|
| Molecular Weight |
442.54
|
| Exact Mass |
441.979
|
| CAS # |
65501-24-8
|
| PubChem CID |
2733162
|
| Appearance |
Off-white to light yellow solid powder
|
| Boiling Point |
614.2ºC at 760 mmHg
|
| Melting Point |
182 °C (dec.)(lit.)
|
| Flash Point |
325.2ºC
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[K+].[K+].[K+].O([H])C(C([H])([H])N(C([H])([H])C(=O)[O-])C([H])([H])C([H])([H])N(C([H])([H])C(=O)[O-])C([H])([H])C(=O)[O-])=O.O([H])[H].O([H])[H]
|
| InChi Key |
MAPFUJCWRWFQIY-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C10H16N2O8.3K.2H2O/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;;2*1H2/q;3*+1;;/p-3
|
| Chemical Name |
tripotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;dihydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2597 mL | 11.2984 mL | 22.5968 mL | |
| 5 mM | 0.4519 mL | 2.2597 mL | 4.5194 mL | |
| 10 mM | 0.2260 mL | 1.1298 mL | 2.2597 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
